Biochemical nature and mapping of PSMA epitopes recognized by human antibodies induced after immunization with gene-based vaccines
- PMID: 16334167
Biochemical nature and mapping of PSMA epitopes recognized by human antibodies induced after immunization with gene-based vaccines
Abstract
Background: A possible new target for immunotherapy is the prostate-specific membrane antigen (PSMA). The aim of the present study was to define potential PSMA epitopes for antibody binding using sera from patients immunized with gene-based anti-PSMA vaccines.
Materials and methods: Sera from prostate cancer patients, immunized repeatedly with plasmid and adenoviral vectors, each encoding for the extracellular portion of human PSMA, were tested for anti-PSMA antibodies by Western blot. PSMA-producing LNCaP cells were used as a control. Recombinant PSMA protein cleaved with different proteinases was used for epitope mapping. Different enzymes were used to cleave the PSMA molecule.
Results: Specific anti-PSMA antibodies were detected in the studied patients' sera, mainly against the PSMA protein core. An alignment of the predicted enzyme-cleavage fragments was compared with Western blot results and several antibody epitopes were determined.
Conclusion: These data demonstrate that multiple gene-based vaccinations induce an anti-PSMA humoral immune response. The antibodies are predominantly specific for the PSMA protein core.
Similar articles
-
Humoral immune response in prostate cancer patients after immunization with gene-based vaccines that encode for a protein that is proteasomally degraded.Cancer Immun. 2005 Jan 11;5:1. Cancer Immun. 2005. PMID: 15641767 Clinical Trial.
-
DNA fusion gene vaccines induce cytotoxic T-cell attack on naturally processed peptides of human prostate-specific membrane antigen.Eur J Immunol. 2011 Aug;41(8):2447-56. doi: 10.1002/eji.201141518. Epub 2011 Jul 4. Eur J Immunol. 2011. PMID: 21604260
-
Immune responses against PSMA after gene-based vaccination for immunotherapy-A: results from immunizations in animals.Cancer Gene Ther. 2006 Apr;13(4):436-44. doi: 10.1038/sj.cgt.7700914. Cancer Gene Ther. 2006. PMID: 16276349
-
DNA vaccines: an active immunization strategy for prostate cancer.Semin Oncol. 2003 Oct;30(5):659-66. doi: 10.1016/s0093-7754(03)00356-7. Semin Oncol. 2003. PMID: 14571413 Review.
-
Targeting novel antigens for prostate cancer treatment: focus on prostate-specific membrane antigen.Expert Opin Ther Targets. 2005 Jun;9(3):561-70. doi: 10.1517/14728222.9.3.561. Expert Opin Ther Targets. 2005. PMID: 15948673 Free PMC article. Review.
Cited by
-
Prostate Cancer Immunotherapy: Exploiting the HLA Class II Pathway in Vaccine Design.J Clin Cell Immunol. 2015 Aug;6(4):351. doi: 10.4172/2155-9899.1000351. Epub 2015 Aug 26. J Clin Cell Immunol. 2015. PMID: 26807308 Free PMC article.
-
Considering the potential for gene-based therapy in prostate cancer.Nat Rev Urol. 2021 Mar;18(3):170-184. doi: 10.1038/s41585-021-00431-x. Epub 2021 Feb 26. Nat Rev Urol. 2021. PMID: 33637962 Review.
-
Enhancing cellular cancer vaccines.Immunotherapy. 2009 May;1(3):495-504. doi: 10.2217/IMT.09.4. Immunotherapy. 2009. PMID: 20352015 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous